- Home
- MDGL vs HSIC Comparison
MDGL vs HSIC Comparison
Compare MDGL & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- HSIC
- Stock Information
- Founded
- MDGL 2011
- HSIC 1932
- Country
- MDGL United States
- HSIC United States
- Employees
- MDGL N/A
- HSIC N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- HSIC Medical Specialities
- Sector
- MDGL Health Care
- HSIC Health Care
- Exchange
- MDGL Nasdaq
- HSIC Nasdaq
- Market Cap
- MDGL 6.8B
- HSIC 8.1B
- IPO Year
- MDGL N/A
- HSIC 1995
- Fundamental
- Price
- MDGL $319.93
- HSIC $66.23
- Analyst Decision
- MDGL Buy
- HSIC Buy
- Analyst Count
- MDGL 9
- HSIC 10
- Target Price
- MDGL $386.29
- HSIC $81.10
- AVG Volume (30 Days)
- MDGL 333.2K
- HSIC 1.4M
- Earning Date
- MDGL 05-01-2025
- HSIC 05-05-2025
- Dividend Yield
- MDGL N/A
- HSIC N/A
- EPS Growth
- MDGL N/A
- HSIC N/A
- EPS
- MDGL N/A
- HSIC 3.05
- Revenue
- MDGL $180,133,000.00
- HSIC $12,673,000,000.00
- Revenue This Year
- MDGL $230.69
- HSIC $4.68
- Revenue Next Year
- MDGL $74.76
- HSIC $3.63
- P/E Ratio
- MDGL N/A
- HSIC $21.47
- Revenue Growth
- MDGL N/A
- HSIC 2.71
- 52 Week Low
- MDGL $189.00
- HSIC $60.56
- 52 Week High
- MDGL $377.46
- HSIC $82.49
- Technical
- Relative Strength Index (RSI)
- MDGL 50.76
- HSIC 48.07
- Support Level
- MDGL $276.20
- HSIC $62.40
- Resistance Level
- MDGL $330.64
- HSIC $66.92
- Average True Range (ATR)
- MDGL 20.79
- HSIC 2.74
- MACD
- MDGL 0.06
- HSIC 0.35
- Stochastic Oscillator
- MDGL 76.56
- HSIC 89.15
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.